免疫疗法在临床肺癌治疗中是必需的辅助方法。单一免疫辅助疗法由于其药物代谢快速，不能高效累积在肿瘤部位，未能展现期望的临床治疗效果。免疫原性死亡（ICD）是新型的抗肿瘤策略，结合免疫辅助剂使用。它可以提供肿瘤相关抗原，激活树突状细胞，并吸引淋巴细胞进入肿瘤微环境。本研究使用多柔比星诱导的肿瘤细胞膜包裹的铁（II）-胞嘧啶-腺嘌呤纳米粒（DM@NPs）有效地共同传递肿瘤相关抗原和辅助剂。DM@NPs表面的ICD相关膜蛋白更高表达导致DCs对DM@NPs的吞噬增强，从而促进DCs的成熟和前炎细胞因子的释放。DM@NPs可以显著增加T细胞浸润，重构肿瘤免疫微环境并在体内抑制肿瘤进展。这些发现揭示了预诱导ICD肿瘤细胞膜包裹纳米粒可以增强免疫疗法反应，为肺癌提供了有效的仿生纳米材料基础的治疗策略。 ©2023 Wiley-VCH GmbH。

Immunotherapy is a required adjuvant method in lung cancer therapy clinically. The single immune adjuvant failed to show the expected clinical therapeutic efficacy due to its rapid drug metabolism and inability to accumulate in the tumor site efficiently. Immunogenic cell death (ICD) is a new anti-tumor strategy combined with immune adjuvants. It can provide tumor-associated antigens, activate dendritic cells, and attract lymphoid T cells into the tumor microenvironment. Here doxorubicin-induced tumor membrane-coated iron (II)-cytosine-phosphate-guanine nanoparticles (DM@NPs) are shown for efficient co-delivery of tumor-associated antigens and adjuvant. Higher expression of ICD-related membrane proteins on the surface of the DM@NPs leads to the enhanced uptake of DM@NPs by dendritic cells (DCs), thereby promoting the DCs maturation and pro-inflammatory cytokines release. DM@NPs can remarkably increase the T cell infiltrations, remodel the tumor immune microenvironment and inhibit tumor progression in vivo. These findings reveal that pre-induced ICD tumor cell membrane-encapsulated nanoparticles can enhance immunotherapy responses and provide an effective biomimetic nanomaterial-based therapeutic strategy for lung cancer.© 2023 Wiley-VCH GmbH.